Resmed (RSMDF) Depreciation & Amortization (CF) (2009 - 2026)

Resmed (RSMDF) has reported Depreciation & Amortization (CF) for 18 consecutive years, with $44.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) fell 29.63% year-over-year to $44.8 million; the trailing twelve-month figure through Jun 2026 stood at $201.3 million (up 1.45% YoY), and the FY2026 full-year result was $201.3 million, up 1.45% from the prior year.
• Depreciation & Amortization (CF) eased to $44.8 million in Q2 2026 per RSMDF's latest filing, from $59.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $63.6 million in Q2 2025 and bottomed at $36.3 million in Q3 2022.
• Historically, Depreciation & Amortization (CF) has averaged $45.6 million across 5 years, with a median of $44.8 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) soared 45.68% in 2025, then decreased 29.63% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $37.8 million in 2022, then increased by 18.58% to $44.8 million in 2023, then rose by 3.7% to $46.4 million in 2024, then advanced by 7.42% to $49.9 million in 2025, then retreated by 10.24% to $44.8 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $44.8 million, $59.0 million, and $49.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.